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Major contributors to atherosclerosis are oxidative damage and endoplasmic reticulum (ER) stress-induced apoptosis; both of
whichcanbediminishedbytheanti-oxidativeproteinparaoxonase-2(PON2).ERstressisalsorelevanttocancerandassociated
with anti-cancer treatment resistance. Hence, we addressed, for the ﬁrst time, whether PON2 contributes to tumorigenesis and
apoptotic escape. Intriguingly, we found that several human tumors upregulated PON2 and such overexpression provided
resistance to different chemotherapeutics (imatinib, doxorubicine, staurosporine, or actinomycin) in cell culture models. This
was reversed after PON2 knock-down. Remarkably, just deﬁciency of PON2 caused apoptosis of selective tumor cells per se,
demonstrating a previously unanticipated oncogenic function. We found a dual mechanistic role. During ER stress, high
PON2 levels lowered redox-triggered induction of pro-apoptotic CHOP particularly via the JNK pathway, which prevented
mitochondrial cell death signaling. Apart from CHOP, PON2 also diminished intrinsic apoptosis as it prevented mitochondrial
superoxide formation, cardiolipin peroxidation, cytochrome c release, and caspase activation. Ligand-stimulated apoptosis by
TRAIL or TNFa remained unchanged. Finally, PON2 knock-down caused vast reactive oxygen species formation and stimulated
JNK-triggered CHOP expression, but inhibition of JNK signaling did not prevent cell death, demonstrating the pleiotropic,
dominating anti-oxidativeeffectof PON2.Therefore, targetingredox balance is powerful to induce selective tumor cell death and
proposes PON2 as new putative anti-tumor candidate.
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Cell death can be induced by ligand–receptor interactions,
designated as extrinsic apoptotic pathway, whereas intrinsic
signaling results from intracellular malfunctions. Protein
(dys)functions may be discriminated from organelle-based
pathways, such as stress at the endoplasmic reticulum (ER),
or nuclear DNA damage. These pathways intersect and
impact on cell death, which contributes to numerous human
illnesses characterized either by excessive cell death, or
resistance to apoptosis. Knowledge of crucial factors and
steps is critical as their effects may be both appreciated and
detrimental.
Many newly synthesized proteins pass the ER and require
sumptuous modiﬁcations. Any disturbance induces ER stress
and activates the unfolded protein response (UPR) pathway.
Although its primary goalis to assist cell survival, this pathway
canultimatelyinitiatecelldeathandrelatestoatherosclerosis,
diabetes, or neurodegeneration.
1 Additionally, the UPR is
critically engaged in the balance between apoptosis or
outgrowth of cancer cells
2 and therefore therapeutically
targeted. The UPR is a deﬁned progression of events
involving only few ER transmembrane proteins: (I) activation
ofthekinasePERK;thisphosphorylateseIF2a,whichinduces
transcription factor ATF4 and blocks translation; (II) activation
of IRE1, which triggers protein kinase JNK and produces
transcriptionfactorXBP1byanunconventionalsplicingevent;
and (III) processing and activation of ATF6.
1 This leads to
transcriptional induction of chaperones and the pro-apoptotic
CHOP protein. In case of insurmountable ER stress, CHOP
fundamentally initiates apoptosis, as highlighted by the fact
that CHOP deﬁciency enhanced resistance to diverse
cytotoxic stimuli.
3,4
Also, mitochondria are centrally involved in the execution of
cell death. Upon receiving toxic stimuli mitochondria produce
excess reactive oxygen species (ROS), that is, superoxide
O2
 . Spontaneous or catalyzed dismutation of O2
  generates
H2O2. This is a substrate for cytochrome c, which in turn
catalyzes the H2O2-dependent peroxidation of cardiolipin, a
lipid found almost exclusively at the inner mitochondrial
membrane. Cardiolipin peroxidation causes mitochondrial
cytochromecrelease,whichpromotesapoptosomeformation
and links ROS production with apoptosis.
5 Importantly, we
showed that the human enzyme paraoxonase-2 (PON2)
diminished not only ROS but also ER stress-induced
apoptosis.
6
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www.nature.com/cddisPON2 is one of three highly conserved members of the
paraoxonase family of enzymes consisting of PON1, PON2,
and PON3. In contrast to PON1 and PON3, PON2 is not
present in serum lipoprotein fractions, but an intracellular
protein found in almost every tissue, particularly at the
perinuclear region, ER and mitochondria.
6–8 Again contrast-
ing with PON1, PON2 shows predominant lactonase activ-
ity.
9–11 Natural substrates remain unknown albeit PON2, as
part of the innate immune system, appears involved in the
defense against infections by the human pathogen Pseudo-
monas aeruginosa.
12–14 Paraoxonases are important detox-
ifyingandanti-oxidativeenzymes,whichestablishestheirrolein
organophosphate poisoning, diabetes, obesity, cardiovascular
diseases, and innate immunity.
11,15 In mice, PON levels
negatively correlated with atherosclerosis.
16–18 Consistently,
several studies demonstrated that PON2 protected macro-
phages, vascular and other cells against oxidative stress,
whereas its downregulation reversed this effect.
6,7,19 The
cytoprotective effect of PON2 is well established. However, it
is fully enigmatic how PON2 reduced apoptosis, whether this is
restricted to certain pathways and what the pathophysiological
relevance could be. These issues are addressed in this study.
Although neglected and not primarily addressing PONs,
some (microarray) studies observed marked overexpression
of PON2 in cancers, for example, in hepatocellular carcino-
ma,
20 prostate carcinoma
21 or lymphocytes infected with T-
cell leukemia virus
22 PON2 was also highly upregulated in
gene expression proﬁling studies addressing pediatric acute
lymphoblastic leukemia (ALL).
23 In another study, PON2 was
among a small group of upregulated genes that characterized
pediatric ALL patients with very poor outcome prognosis and
the potential to prospectively identify patients who fail current
therapeutic regimens.
24 Interestingly, PON2 was also present
in an outcome-speciﬁc gene expression signature that
characterized chronic myeloid leukemia (CML) patients
resistant to front-line therapeutic imatinib.
25 Given the anti-
apoptotic role of PON2
6,26 and the fact that apoptotic escape
represents a major clinical complication, we asked whether
PON2 overexpression contributes to cancer as it confers
apoptosis resistance. This is the ﬁrst report that investigates
the expression of PON2 in various human tumor samples, its
involvement incancer cell signaling and impact on cytotoxicity
of chemotherapeutics. Our results are of great importance,
giventhat targetingof redox balance in tumorsrecently turned
into an attractive and very potent tool in cancer therapy.
Results
PON2 is overexpressed in tumors and its knock-down
causes death of selective tumor cells. PON2
overexpression, in contrast to its knock-down, diminished
ER stress-induced cell death and prevented mitochondrial
superoxide production.
6,26–28 The latter regulates
cytochrome c liberation from mitochondria
5 and may thus,
explain how PON2 counteracts atherosclerosis, for example,
by protecting vascular cells and macrophages from cell
death. However, potential drawbacks of this cytoprotective
effect or diseases other than atherosclerosis have never
been tested. Cancer appeared relevant, because effects
such as that of PON2 are frequently exploited by tumors.
Therefore, we analyzed PON2 cDNA levels in cancer survey
panels covering 4430 different samples from various normal
versus diseased tissues (Figure 1a). Although no augmented
PON2 levels were observed in some cases, moderate
overexpression (B1.5-fold) was seen in tumors of thyroid
gland, prostate, pancreas, and testis. Higher PON2 levels
were found in tumors from endometrium/uterus, liver, kidney,
lymphoid tissues, or urinary bladder (B2–4-fold). An
upregulation of PON2 and its relevance are supported by
recent studies that found high PON2 levels in association
with poor prognosis in cohorts of pediatric ALL
23,24 or with
imatinib resistance in CML patients.
25 We next analyzed
protein expression in selected lysates from pools of normal
versus tumor tissues (Figure 1b). No upregulation was seen
in spleen tumors, and a moderate PON2 overexpression in
pancreas and lung tumors. In concordance with above cDNA
panels, kidney and liver tumors doubled PON2 protein levels.
Over 10-fold upregulation of PON2 was found in thymus
tumors and non-Hodgkins lymphomas (the latter is 1.7-fold
when normalized to lymph node instead of peripheral
leukocytes).
We hypothesized that PON2 contributes to apoptotic
escape of tumor cells and tested whether chemotherapeutic-
triggered cell death correlated with its expression level.
Indeed, stable overexpression of PON2-GFP or PON2-HA
in endothelial cells reduced the dose-dependent activation of
caspase-3 and intracellular ATP decrease in response to the
anthracycline doxorubicin (Figure 1c). Similarly, increased
PON2 levels prevented death of Bcr-Abl-positive K562
leukemia cells in response to front-line therapeutic imatinib,
a Bcr-Abl kinase inhibitor (Figure 1d). This likely explains the
contribution of PON2 to imatinib resistance in primary
resistant CML patients.
25 As PON2 upregulation provided
apoptotic escape (Figures 1c and d and below), we tested
whether PON2 deﬁciency reversed this effect to enhance
susceptibility to chemotherapeutics. Indeed, RNAi-mediated
knock-down of PON2 was even additive to imatinib-triggered
K562 cell death and enhanced apoptosis rates (Figure 1e and
SupplementaryFigures1A).Strikingly,however,weobserved
that just PON2 knock-down caused signiﬁcant cell death even
in the absence of pro-apoptotic stimulation (Figure 1e), which
wasunexpectedgiventhe viability ofPON2-deﬁcientmice. To
expandthistoothertumorcelllines,PON2wasknockeddown
inK562leukemiacells,A549lungcarcinomacells,endothelial
EA.hy926cells, Huh7and HepG2hepatoma cells, embryonic
kidney HEK293 cells, and Jurkat T-cell leukemia cells. We
analyzed, 3 days later, apoptosis rates by ﬂow cytometry
(Figure 1f and Supplementary Figure s1A). Huh7 (or HepG2;
not shown), Jurkat, and HEK293 cells did not react to PON2
knock-down.Thiscontrastswithseverelyincreasedapoptosis
of K562, A549, and EA.hy 926 cells. As apoptosis required no
further stimulation to proceed, we revealed an unanticipated
oncogenic role for PON2, apparently of special importance for
leukemias or lung cancer. Therefore, we next addressed its
mechanism.
PON2 reduces UPR-triggered induction of pro-apoptotic
CHOP. Previous data linked PON2 with ER stress-induced
cell death.
6,26 To discriminate apoptotic pathways and reveal
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Cell Death and Diseaseunderlying mechanism(s), we ﬁrst tested PON2’s effect on
transcriptional induction of CHOP, a very potent
pro-apoptotic factor critically involved in ER stress (and
below
3). Naive or PON2-GFP overexpressing cells were
challenged with tunicamycin to induce ER stress.
Tunicamycin time-dependently increased CHOP mRNA and
Figure 1 PON2 is overexpressed in several tumors and its deﬁciency causes death of some tumor cells. (a) PON2 cDNA expression levels were determined in cancer
versus normal tissues by quantitative real-time PCR using TissueScan cancer survey/lymphoma panels containing >430 samples from various tumors. (b) Mixed donor
samplesfromtheindicatedprimaryhealthyortumortissueswereanalyzedforPON2,GAPDH,andp38MAPKexpressionbywesternblotting.Lowerpanelshowsquantitative
evaluation. The 12-fold upregulation in non-Hodgkins lymphoma is 1.7-fold when normalized to lymph node instead of peripheral leukocytes. (c) Endothelial EA.hy 926 cells
werestimulatedwiththeindicatedconcentrationsofdoxorubicinandassessedforcaspase-3/7activity(left;16h)orintracellularATPlevel(right;24h).(d)K562cellswereleft
untreated or were transfected with PON2-GFP. Next day, the cells were treated for 24h with imatinib and analyzed for cell death by ﬂow cytometry. Only GFP-positive cells
were counted and calculated as fold increase in apoptosis. GFP-transfected K562 behaved as untreated (not shown). (e) K562 cells were left untreated or were transfected
with scrambled (control) or PON2-speciﬁc siRNAs. After 3 days, imatinib was added for 24h and cells were analyzed as above. (f) Indicated cells were left untreated or were
treated with scrambled or PON2-speciﬁc siRNAs. Three days later, cell death was assessed by FACS. Results for Huh7 cells were exchangeable with HepG2; Jurkat-T-cells
did not express signiﬁcant PON2 protein levels (not shown). Symbols represent mean±S.E.M.; n¼3–6 (c–e); n.s.¼not signiﬁcant; *Po0.05; ***Po0.001
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Cell Death and Diseaseprotein levels, but this was substantially lower in PON2-
overexpressing cells (Figures 2a and b). Given the impact of
CHOP on cell death, this effect likely explains the protective
role of PON2, at least in part and in response to ER stress. In
order to test this hypothesis and because apoptotic efﬁcacy
of CHOP may relate to cell type and stimulus, CHOP was
knocked down by siRNA (Figure 2c). Subsequently, we
monitored tunicamycin-induced apoptotic processes. Figures
2d–f show that abrogated CHOP expression correlated with
reduced levels of cardiolipin peroxidation, preserved
mitochondrial membrane potential DCM, absent nuclear
condensation, and low caspase-3 activation. Hence, CHOP
is centrally involved in signaling from ER to mitochondria and
a decrease of its induction, as resembled by high PON2
levels, is sufﬁcient to avert ER stress-induced apoptosis.
PON2 has an enzymatic lactonase activity and it reduces
oxidative stress. To distinguish which function diminished
CHOP induction, we used PON2 point-mutations H
114Qo r
H
133Q, as these blunted its lactonase, but not anti-oxidative
activity.
27 These PON2-mutants reduced CHOP induction
and cell death indistinguishable from PON2-wildtype (see
Figure 3a for CHOP and
27 for caspase-3 activation, intracel-
lular ATP levels and apoptosis). This discloses PON2’s anti-
oxidative effect as basis for its anti-apoptotic function. Yet,
there is no mutation known that abrogates PON2’s impact on
ROS, so we veriﬁed that established anti-oxidative mechan-
isms also attenuated CHOP expression. Naive cells were
loaded with cell-permeable superoxide dismutase (PEG-
SOD; 100U/ml) or N-acetyl cysteine (NAC; 10mM)2 4 h
before addition of tunicamycin. Both treatments diminished
ROS production (not shown) and CHOP activation (Figures
3b and c), which conﬁrms the impact of ROS secondary to ER
stress.
PON2 reduces CHOP induction by lowering JNK
signaling. We next addressed how PON2 decreased
CHOP induction. First, we analyzed the c-Jun N-terminal
kinase (JNK) pathway, because ER stress produces ROS
that can activate JNK,
29,30 which in turn can be upstream and
downstream of the UPR and CHOP. Given that PON2
diminished ER stress-induced ROS and because anti-
oxidants lowered CHOP induction (and above
6), we
suggested that PON2 decreased CHOP by acting on ROS-
activated JNK. Indeed, tunicamycin-triggered JNK activation
(i.e., Thr
183/Tyr
185 phosphorylation) was signiﬁcantly lower in
PON2-overexpressing cells (Figure 3d). Consequently, we
veriﬁed that JNK inhibition reduced CHOP expression in
naive but not PON2-overexpressing cells. This was
assessed by pharmacological and genetic approaches.
The JNK inhibitor SP600125 signiﬁcantly lowered
tunicamycin-triggered CHOP induction in naive cells
(Figure 3e), demonstrating that in this system JNK is
upstream of CHOP expression. This effect was absent in
PON2 overexpressing cells (Figure 3e). JNK knock-down by
siRNA also decreased CHOP induction in naive but not in
PON2-overexpressing cells (Figure 3f and Supplementary
Figure S1B). Concordantly, CHOP induction in naive cells
with SP600125 or JNK siRNA did not signiﬁcantly differ from
that in PON2-overexpressing cells without such stimulation.
Next, we veriﬁed the speciﬁcity of PON2 for the JNK-
CHOP-axis. CHOP induction in response to ER stress is
mainly mediated by activation of the three UPR branches
transduced by IRE1, PERK, and ATF6. To determine PERK
activation, we measured eIF2a phosphorylation and ATF4
induction. Figure 4a shows an increase in phospho-eIF2a
levels 2h after tunicamycin addition, which gradually
increased over time. This was identical in naive and PON2-
overexpressing cells. Further, PON2 overexpression did not
alter induction of ATF4 mRNA or protein (Figure 4b and not
shown). In a similar manner, IRE1-mediated splicing of XBP1
mRNA was unaffected by PON2 overexpression (Figure 4c).
Processing and thus activation of ATF6 by Site-1 and Site-2
proteases was also independent from PON2 levels
(Figure 4d). Hence, we demonstrate that PON2 overexpres-
sion counteracts cell death by balancing ROS levels. During
ER stress, this holds CHOP at bay and could be achieved as
PON2 via ROS controls JNK activation (and not by acting on
PERK, IRE1, or ATF6 signaling). In agreement with such
model, PON2 knock-down is sufﬁcient to induce vast ROS
production(Figure 5a). Still inaccord, it also causes moderate
CHOP expression (Figure 5b), however, viability loss after
PON2knock-downisnotpreventedbyinhibitedJNKsignaling
(Figure 5c), which reveals that additional effects (disturbed
mitochondrial redox homeostasis; see below) dominate over
the induction of CHOP.
PON2 also protects against intrinsic apoptotic
signaling. We next assessed PON2’s effect on ER stress-
unrelated apoptosis. To this end, cells were treated with
additional chemotherapeutics and established inducers of
intrinsic apoptosis, such as PKC inhibitor staurosporine or
transcription inhibitor actinomycin D. These compounds
failed to induce CHOP (Supplementary Figure S1C), so
effects are independent from this protein. Staurosporine
treatment (0.5mM; 16h) caused pronounced apoptosis in
naive cells (B77%), which was strongly reduced in PON2-
overexpressing cells (B33%; Figure 6a). A closely similar
tendency was seen after actinomycin D treatment (5mg/ml;
24h; Figure 6a). Given the protection afforded by higher
PON2 levels, we traced upstream effects and monitored
Figure 2 PON2 reduces induction of pro-apoptotic CHOP. (a and b) Naive or PON2-GFP overexpressing EA.hy 926 cells were treated with tunicamycin (1mg/ml) for the
indicated time and analyzed for CHOP mRNA and protein levels (AþB, respectively). (c) Naı ¨ve EA.hy cells were left untreated (control), or transfected with scrambled or
CHOP-speciﬁc siRNAs. Nextday, cells were treatedwith solvent(left) or tunicamycin(1mg/ml; 6h) and analyzedfor CHOP and a-tubulin protein levels.(d) Control or siRNA-
treated naive cells were stimulated with tunicamycin (1mg/ml; 48h) followed by cardiolipin staining by NAO and analysis by a ﬂuometer. Fluorescence decrease indicates
cardiolipin peroxidation. (e) Scrambled- or CHOP-siRNA-treated cells were tunicamycin-stimulated for 48h and analyzed for caspase-3 activation. Symbols represent
mean±S.E.M.n¼3–9;n.s.¼notsigniﬁcant;**Po0.01;***Po0.001.(f)UntreatedorCHOP-siRNAtreatedcellswerestimulatedwithtunicamycinasbefore(48h),stained
for mitochondrial membrane potential (DCM; by DiOC6) and nuclei, and analyzed by confocal laser-scanning microscopy. Arrows indicate cells with lost membrane potential
and nuclear condensation. Images are representative of several others
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Cell Death and Diseasecaspase signaling. As expected, activation of caspases 8, 9,
and 3 in response to these treatments was signiﬁcantly lower
in PON2-overexpressing cells (Figure 6b).
Confocal microscopy of live cells revealed that PON2
signals overlapped with both ER and mitochondria (Supple-
mentary Figure S2), which conﬁrms previous biochemical
approaches and also more recent data reporting individual
mitochondrial PON2 functions.
6,27,28 Because mitochondria
can be crucial to apoptosis and upstream of caspases, we
applied a FACS-based approach to test whether PON2
affected cytochrome c release. Staurosporine induced a
dose-dependent increase in mitochondrial cytochrome c
liberation in naive cells (Figure 7a, left). This was substantially
diminished in cells overexpressing PON2 (Figure 7a, right),
which explains the reduced apoptosis rates described above.
To address whether PON2 has direct mitochondrial functions
or affects cytoplasmic caspase feedback loops, staurospor-
ine-induced cytochrome c release was assessed in the
presence of pan-caspase inhibitor, Z-VAD-fmk. This blocked
caspases 8, 9, and 3/7, but did not prevent cytochrome c
release (Supplementary Figure S3), suggesting that PON2
functions at the mitochondria.
We next analyzed peroxidation of cardiolipin, a lipid at the
inner mitochondrial membrane that critically controls cyto-
chrome c release.
31 Staurosporine dose-dependently caused
cardiolipin peroxidation in naive cells, whereas PON2-over-
expressingcellsweresubstantiallymoreresistant(Figure7b).
Cardiolipin peroxidation is preceded by excess mitochondrial
O2
  generation. We ﬁnally demonstrate that PON2 counter-
acts such event: Cells with or without stable PON2-HA
overexpression were labeled with Mito-HE (mitochondria-
targeted dihydroethidium), treated with complex III-inhibitor
antimycin A to induce O2
 , and analyzed by a ﬂuorometer or
FACS at wavelengths speciﬁc for O2
 -induced Mito-HE
products. The pronounced accumulation of mitochondrial
O2
  observed in naive cells was signiﬁcantly lower in
Figure 3 PON2 diminishes CHOP induction by lowering JNK activation. (a) Endothelial cells overexpressing PON2-WT-GFP or lactonase-deﬁcient PON2-H
114Q-GFP
weretreatedwithtunicamycin(1mg/ml;8h)andanalyzedforCHOPmRNAlevels.(bandc)Naı ¨veEA.hycellsweretreatedwithPEG-SOD(100U/ml)orNAC(10mM)for24h
before addition of tunicamycin and quantiﬁcation of CHOP mRNA (b) or protein (c). (d) Naive or PON2-GFP overexpressing cells were tunicamycin-stimulated (1mg/ml;
30min)andanalyzedforJNK-phosphorylation(foldincreaseshownbelow).GAPDHproteinlevelsservedasloadingcontrol.Similarresultswereobtainedforothertimepoints
and in multiple experiments. (e) Indicated cells were treated with tunicamycin (1mg/ml; 8h) or JNK inhibitor SP600125 (10mM) or both, followed by CHOP mRNA
quantiﬁcation. (f) Named cells treated with scrambled (Ctrl) or JNK-speciﬁc siRNA were stimulated with tunicamycin (1mg/ml; 8h), followed by CHOP mRNA quantiﬁcation.
Symbols represent mean±S.E.M. n¼3–9; n.s.¼not signiﬁcant; *Po0.05; **Po0.01; ***Po0.001
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Cell Death and DiseasePON2-overexpressing cells (Figure 7c and Supplementary
Figure S4A). Similarly, antimycin-treated mitochondria iso-
lated from PON2-HA-overexpressing cells produced less O2
 
than those from controls (Supplementary Figure S4B). Two
contemporary analyses revealed that PON2 prevents O2
 
productionbecauseofaninteraction withcoenzyme Q10.
27,28
Also, PON2 wildtype and lactonase-deﬁcient mutants were
equally protective against intrinsic apoptosis.
27 Thus, PON2
diminishespro-apoptoticmitochondrial O2
 burststhatprevent
cardiolipin peroxidation, cytochrome c release, caspase
activation, and cell death.
PON2 does not impact on extrinsic apoptotic
pathways. In contrast to intrinsic apoptosis, PON2 failed
to attenuate extrinsic signaling. This is demonstrated by the
fact that PON2 did not alter any level of signal transmission
in response to death receptor-dependent apoptosis by
TRAIL, as documented by activation of caspase-8 after 2h,
caspase-3 after 6h and cell death after 16h (Figures 8a–c,
respectively). PON2 also did not decrease caspase-3
activation in response to TNFa/actinomycin D co-treatment
(Figure 8d). Hence, PON2 is ineffective when ligand-
mediated stimuli are sufﬁciently strong to activate caspase-
cascades at the receptor complex (type-I cells). A schematic
summary of PON2’s anti-apoptotic function is depicted in
Supplementary Figure S5.
Discussion
Treatment of malignancies is often hampered because tumor
cells modulate execution of the cell death program to promote
apoptosis resistance, which contributes to failure of immuno-
surveillance and therapeutic approaches. This can be
achieved by potentiation of anti-apoptotic or attenuation of
pro-apoptotic signaling. The mechanistic insight provided in
this study and the result that several tumors overexpress
PON2, combined with the ﬁnding that PON2 deﬁciency
destabilizes tumor cells, led us to propose PON2 as novel
putative anti-tumor target.
PON2 overexpression signiﬁcantly protected cells from
oxidative stress and, more importantly, from ER stress-
induced apoptosis.
6,26 It was totally unsolved, however, how
the diminished caspase activation was achieved and whether
this was limited to ER stress. We here revealed that PON2
overexpression diminished the induction of pro-apoptotic
CHOP. Further, we provide evidence that CHOP deﬁciency
prevents cardiolipin peroxidation, loss of mitochondrial
membrane potential, nuclear condensation and caspase
activation in response to ER stress. Given these results and
many other reports that demonstrate the fundamental role of
CHOP,
3,4,32 it is clear that reduced CHOP levels, as
resembled by PON2 overexpression, contribute to cell
survival. One thus may speculate whether the known anti-
atherogenic potential of PON2
18,33 results from its effect on
CHOP, when considering its linkage to atherosclerosis.
34
Figure 4 No alteration of classical ER stress-transducers by PON2. (a) Naive or PON2-GFP overexpressing cells were treated with tunicamycin followed by analysis of
eIF2a Ser
51-phosphorylation and a-tubulin. One representative blot is shown (left); six independent experiments were quantiﬁed (right). (b and c) Similar to A, but analyzing
mRNA levels of ATF4 (c) or spliced XBP1 (d). (d) Named cells were transfected with ATF6-ﬂag plasmid, treated with tunicamycin and analyzed for ATF6-ﬂag and a-tubulin.
Symbols represent mean±SEM; n¼3–12: no signiﬁcant differences were detected
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Cell Death and DiseaseThe UPR IRE1a branch is of particular importance, as it
produces the spliced-XBP1 transcription factor and the IRE1/
TRAF2/ASK1 signaling cascade, which both activates JNK
and induces CHOP.
35,36 Moreover, CHOP induction results
from oxidative stress, which accompanies ER stress
29,37 and
appears upstream of XBP1 and/or JNK.
30 Most likely owing to
its anti-oxidative role during ER stress,
6 PON2 reduces JNK
activation and CHOP induction. Likewise, other studies
revealed a reduced CHOP induction by anti-oxidative inter-
ventions.
3,29 It remains undetermined what particular redox-
sensitive pathway is altered by PON2 to reduce JNK
phosphorylation, because this is beyond our scope and
requires intense investigation in an entirely new though
interesting project. It is a matter of debate that ROS sources
are activated during ER stress and it is presently unknown
whether PON2 reduces ROS only at the mitochondria, or
perhaps also at the ER, or in conjunction, for example, with
NADPH oxidases (as shown for NOX4 in TGF-b stimulated
smooth muscle cells.
6) Similarly, multiple pathways link ROS
with JNK activation, such as ASK1 (modulated bythioredoxin,
glutaredoxin, PKD, or 14-3-3/PP5), Src kinase, Glutathione
S-transferase Pi, RIP/TRAF2, or IRE1/TRAF2/ASK1.
30
Therefore, a future challenge is to investigate these pathways
and the relatedness to PON2 and to locate the precise
generation of ROS. More straightforward, however, it is
established that PON2 prevents the generation of mitochon-
drial superoxide,
27,28 which controls subsequent apoptotic
pathways similar to cardiolipin peroxidation and cytochrome c
release.
Conceptual advance comes from our ﬁnding that PON2
modulates execution of the cell death program directly at the
mitochondria, thereby allowing modiﬁcation of several apop-
toticpathwaysconvergingat theseorganelles. Inthis manner,
we provide evidence for the ﬁrst time that PON2’s effect is not
limited to ER stress hence, it may be an interesting
pharmacological target, be it to prevent either cell loss or
apoptotic escape. Because PON2 ampliﬁes an already
existing reaction, it may not be confounded by targeting
problems. Moreover, diminished apoptotic signaling is
accomplished at an early step, that is, before a ‘point-of-no-
return’ has been passed due to cardiolipin peroxidation and
subsequent cytochrome c release. Large-scale analyses
must address which speciﬁc tumors upregulate PON2,
whether this is subtype and/or stage-speciﬁc and what
pathways are involved. A simple explanation is that chromo-
some-7,whichharborsthePONcluster,isampliﬁedinseveral
tumors, such as papillary renal kidney carcinoma cells or
prostate adenocarcinomas. The urokinase plasminogen
activator system may also be relevant, as this is increased
in numerous cancers and upregulates PON2.
38 Given that
high basal PON2 levels did not correlate with high sensitivity
to its knock-down, future studies should test larger tumor cell
panels for PON2 deﬁciency-simulated cell death.
Our study revealed lacking protection by PON2 against
receptor-triggered signaling. Upon ligand binding, the recep-
tor recruits the Fas-associated death domain protein FADD,
thereby forms the death-inducing signaling complex , which
activates, for example, caspase-8. Because this sufﬁciently
activates several other caspases, execution of apoptosis is
unaltered, for example, by mitochondrial acting Bcl-2 proteins
in so-called type-I cells; however, some receptor-triggered
pathways also employ mitochondrial ampliﬁer feed-back
loops via Bid cleavage in type-II cells, which led to the
proposal of two distinct but overlapping routes to cell death.
39
Inagreement, PON2alteredcaspase-8activationinresponse
to staurosporine and actinomycin but not TRAIL. The fact that
PON2 did not alter ligand-induced caspase activation or cell
death argues against a role on receptor-triggered apoptosis in
type-I cells.
Several studies demonstrated that PON2 deﬁciency pre-
disposes to vascular complications and atherosclerosis.
11,18
Likewise, PON2 may impact on diabetes, given the impor-
tance of ER stress, JNK signaling and CHOP expression for
Figure 5 PON2 knock-down induces ROS production and CHOP expression,
but viability loss does not depend on JNK signaling. (a) A549 cells were left
untreated (control) or were treated with PON2 siRNA for 2 days, stained for
intracellular oxidative stress with H2-DCFDA and analyzed by FACS. Scrambled
siRNA behaved as control (not shown). Cells above threshold line are considered
ROS positive. (b) A549 cells were left untreated or were treated with scrambled or
PON2 siRNA for 3 days and analyzed for CHOP and PON2 mRNA expression.
(c) A549 cells were left untreated or were treated for 2 days with scrambled, PON2,
or JNK speciﬁc siRNAs, or SP600125 (10mM), or combinations thereof, followed by
determination of intracellular ATP levels
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4Fromsuchperspective,enhancedPON2
expression may be desirable. However, our results disclose
that PON2 upregulation could be detrimental by supporting
apoptosis escape and tumor development. Therefore, the
pharmacological downregulation of PON2 in speciﬁc tumors
may one day add to established cancer therapies.
Materials and Methods
Cell culture, plasmids, and material. Human endothelial EA hy 926 cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium without Phenol Red (Sigma,
St. Louis, MO, USA) containing sodium pyruvate (PAA Laboratories, Pasching,
Austria), antibiotics penicillin/streptomycin, hypoxanthine/aminopterin/thymidine
supplement, GlutaMAX (Invitrogen, Carlsbad, CA, USA) and 10% (v/v) fetal calf
serum (Perbio, Thermo Fisher Scientiﬁc, Waltham, MA, USA). Stable cell lines,
plasmids and transfection procedures were described before.
6,26 HEK293, Jurkat,
K562, and A549 cells were from the German Collection of Microorganisms and Cell
Cultures. K562 and Jurkat cells were cultured in RPMI with phenol red (Sigma),
10% fetal calf serum, sodium-pyruvate, and penicillin / streptomycin. A549 received
the same medium as EA.hy 926, but 5% serum. Cells were cultured at 371Ci n
a humidiﬁed atmosphere under 5% CO2 (10% for EA.hy 926).
Staurosporine,tunicamycin,actinomycinD,antimycinA,polyethyleneglycol(PEG)-
conjugated SOD (PEG-SOD), doxorubicin, N-acetyl-cysteine, imatinib, and SP600125
were purchased from Sigma; Mito-HE was from Molecular Probes (Invitrogen / Life
Technologies); TRAIL and TNFa were from Miltenyi Biotech. Plasmid p3xFLAG-ATF6
was cloned by R Prywes
40 and is distributed as Addgene plasmid 11975 (Addgene).
Figure 6 PON2 overexpression reduces intrinsic pro-apoptotic stimulation. (a) Naive or PON2-HA-overexpressing cells were left untreated or were treated with
staurosporine (0.5mM; 16h) or actinomycin D (5mg/ml; 24h) and examined by ﬂow cytometry. Comparable results were obtained for other concentrations of staurosporine
(0.1–1mM) or actinomycin D (0.5–10mg/ml). (b) Indicated cells were treated for 24h with staurosporine (1mM) or actinomycin D (1mg/ml) and assessed for activation of
caspases 8, 9, and 3/7. *Po0.05; ***Po0.001
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Cell Death and DiseaseFractionation and western blotting. Unless otherwise indicated,tunicamycin
w a su s e dw i t h1mg/ml for 6h; controls contained 0.5%. solvent (DMSO). To monitor
ATF6processing,cellsgrowninsixwellsweretransfected with0.25mgp3xFLAG-ATF6
plus 1.5mg pCDNA3 using Nanofectin (PAA). The low amount of FLAG-ATF6 ensured
tight ER stress regulation. Mitochondria were isolated according to recently published
procedures.
27 Preparation of total protein lysates, SDS-PAGE, and western blotting
using a semi-dry transfer system (Bio-Rad, Hercules, CA, USA) was performed as
before.
6,26 When phospho-antibodies were used, lysates contained Phospho-STOP
(Roche, Basel, Switzerland). For analysis of CHOP and mitochondrial fractions, we
performed tankblots using Bio-Rad’s Mini-Trans-Blot-System and PVDF membranes
(Amersham,ChalfontStGiles,GreatBritain,Hybond-P).Proteincontentwasdetermined
using the bicinchoninic acid protein assay reagent (Pierce, Thermo Fisher Scientiﬁc).
Immunodetected proteins were visualized by Western-Lightning chemiluminescence kit
(Perkin Elmer, Waltham, MA, USA) using X-ray ﬁlm exposure and were quantitatively
evaluated with a ChemiDoc XRS imaging system (Bio-Rad) equipped with QuantityOne
4.6.7 software. All samples were quantitatively normalized to a-tubulin, glycerin-
aldehyde-3-phosphate-dehydrogenase (GAPDH) and/or p38-MAPK.
Antibodies. We used the following antibodies: rabbit-anti-phospho-eIF2a
(Ser51), rabbit-anti-p38-MAPK, rabbit-anti-phospho-SAPK/JNK (Thr183; Tyr185)
(Cell Signaling Technology, Danvers, MA, USA); rabbit-anti-ATF4, mouse-
anti-GAPDH 6C5, rabbit-anti-CHOP F168, goat-anti-Lamin C-20 (Santa Cruz,
Santa Cruz, CA, USA); mouse-anti-Flag M2 (Stratagene, Agilent Techno-
logies, Santa Clara, CA, USA); mouse-anti-Complex III subunit core 2
(MitoSciences, Eugene, OR, USA); mouse-anti-Cytochrome c clone 7H8.2C12.
(BD Biosciences, Franklin Lakes, NJ, USA); rabbit-anti-PON2;
6 mouse-a-Tubulin
Ab2 (Dianova, Hamburg, Germany); mouse-anti-hemagglutinin HA-7 (Sigma);
HRP-conjugated secondary antibodies were from Sigma and Cell Signaling
Technology.
qRT-PCR. RNA was isolated with PeqGold RNA isolation kits from Peqlab.
80ng of RNA was ued for cDNA generation using High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Life Technologies, Carlsbad, CA, USA).
RNA expression levels were quantitatively analyzed using 2ml cDNA, 0.1 unit
Go-Taq polymerase (Promega, Madison, WI, USA), 0.4ml1 0 m M dNTPs and
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Figure 7 PON2 diminishes cytochrome c release, cardiolipin peroxidation and mitochondrial O2
  levels. (a) Indicated cells were stimulated with staurosporine (STS) for
16h and FACS analyzed for mitochondrial cytochrome c. A left shift of the peak indicates cytochrome c liberation. (b) Similar experiment as in (b). Cells were assessed for
cardiolipin peroxidation by NAO staining. A left shift of the peak indicates enhanced cardiolipin peroxidation. (c) Named cells were loaded with Mito-HE and treated with
antimycin (15mM; 2h). O2
 -speciﬁc mitochondrial 2-HE was determined FACS. A right shift of the peak reﬂects mitochondrial superoxide production
PON2 confers apoptosis resistance to cancer cells
I Witte et al
10
Cell Death and Disease20pmol per primer per 20ml reaction in a Bio-Rad Laboratories iCycler.
The following Taqman primers (Euroﬁns MWG Operon) were used: GAPDH: sense
50-CAACAGCCTCAAGATCATCAGC-30; antisense 50-TGGCATGGACTGTGGTCA
TGAG-30;probe50-CCTGGCCAAGGTCATCCATGACAAC-30;CHOP:sense50-GA
CCTGCAAGAGGTCCTGTC-30; antisense 50-CTCCTCCTCAGTCAGCCAAG-30;
probe 50-CACCACTCTTGACCCTGCTT-30; spliced-XBP1: sense 50-GGAGTTAA
GACAGCGCTTGG-30; antisense 50-GCACCTGCTGCGGACTC-30; probe 50-GAA
GCCAAGGGGAATGAAGT-30; PON2: sense 50-TCGTGTATGACCCGAACAAT
CC-30; antisense 50-AACTGTAGTCACTGTAGGCTTCTC-30; probe 50-TCGTCAG
AGGTTCTCCGCATCCAGA-30; JNK1: sense 50-CCACCAAAGATCCCTGACAAG-
30; antisense 50-TGGATGCTGAGAGCCATTG-30; probe 50-ACGGGGGCAGCCCT
CTCCTTTAG-30. Predesigned primers for ATF4 detection were from Applied
Biosystems.
Detection of mitochondrial superoxide, membrane potential
(DWM) and oxidative stress. Assessment of mitochondrial superoxide
was recently described.
27 To monitor DCM, cells seeded in Lab-Tek chamber
slides (Nunc) were treated as indicated, washed with HBSS, stained with 25nM
DiOC6 (Molecular Probes) and Draq5 (Cell Signaling Technology) for 20min at
371C,washed,suspendedingrowthmediumandanalyzedbyconfocalmicroscopy
(see above) under constant conditions (i.e., laser power, gain, pixel dwell etc.). To
detectoxidativestress,cellsweretreatedwithsiRNA(seebelow),incubatedfor2to
3 days, washed with HBSS, labeled with 2.5nM cm-H2DCFDA (Molecular Probes;
30min; 371C), washed, detached, washed, suspended in HBSS, and analyzed by
ﬂow cytometry (see below; FITC ﬁlter set).
Detection of mitochondrial cytochrome c release. Cells grown in
12-welldishes were trypsinized, resuspended in growth medium, pelleted(350 g,
41C, 5min), washed with chilled PBS and re-centrifuged, washed twice in chilled
wash buffer (PBS, 1% FCS, 0.1%. Na-Azide), re-centrifuged and ﬁxed in 4%
paraformaldehyde (in PBS; 20min; 41C). Fixed cells were washed again,
centrifuged, and permeabilized/blocked with PBS containing 0.2% saponin (Fluka,
Sigma Aldrich, St. Louis, MO, USA) and mouse-IgG1k (MOPC-21; Sigma;1:10) for
5minatRT.Afterwashingandcentrifugation,cellswereincubatedwithmouse-anti-
cytochromec(clone7H8.2C12;BDBiosciences;1:20inPBS;20min;41C),washed
and centrifuged, incubated with secondary antibody (AlexaFluor-647 goat anti-
mouse IgG2b; Molecular Probes; 1:40 in PBS; 20min; 41C), washed twice, and
ﬁnallyresuspendedin100ml4%PFA,followedbyadditionof400mlofice-coldPBS
and immediate FACS analysis.
Cardiolipinperoxidation. Cardiolipinwasmeasuredbyincubatingcellswith
acridine orange 10-N-nonyl bromide (NAO; Invitrogen; 50nM; 30min; 371C), which
only bindsnon-peroxidized cardiolipin.Then, cells weretrypsinized,resuspendedin
complete growth medium, pelleted (350 g,4 1C, 5min), washed with PBS,
re-centrifuged, ﬁxed in 2% paraformaldehyde and analyzed by FACS. Alternatively,
cells grown in 96-well plates were stained with NAO as before and analyzed by a
Fluostar-Optima ﬂuometer.
ATP content and caspase activity. To investigate intracellular ATP
content, cells were seeded in opaque 96-well plates and treated next day with the
indicated stimulus and duration. Then, the CellTiterGlo reagent (Promega) was
used as recommended by the supplier. Alternatively, we used Caspase-Glo assays
(Promega) according to the manufacturer’s protocol and previously published data
acquisition.
6
RNA interference. Cells at 60% conﬂuency were transfected with 50nM
PON2-speciﬁc siRNA (50-TTAGTATTCCTCCAGGCTTATCTGG-30; Invitrogen),
35nM CHOP or JNK-speciﬁc smart-pool siRNAs (a mix of four different siRNAs
each; Dharmacon, Thermo Fisher Scientiﬁc) or scrambled siRNA (Invitrogen) using
Saint-Red reagent (Synvolux, Groningen, Netherlands).
Flow cytometry. Cells were stained with annexin-V-phycoerythrin and
7-amino-actinomycin (apoptosis-detection-kit-I; BD Biosciences) as recommend
by the manufacturer; 10000 ﬂuorescent events were acquired using a Facs-Calibur
equipped with CellQuest Pro software (BD Biosciences).
Cancer survey panels. PON2 expression levels were determined in cancer
versus normal tissues by quantitative real-time PCR using TissueScan Cancer
Survey Panel-III (4 96-well format) and Lymphoma Cancer Panel-II (Origene).
Pre-normalized (beta-actin) cDNAs were solubilized (15min on ice) in a 20ml
reaction mix consisting of 10pmol per primer (see above) and the JumpStart Taq
polymerase mix from Sigma. PON2 cDNA levels were quantiﬁed and normalized to
those of GAPDH.Seesupplier’shomepage(http://www.origene.com/qPCR/Tissue-
qPCR-Arrays.aspx) fordetailson thetissuesandcomprehensivepathologyreports.
Real-time qPCR was performed in a Bio-Rad Laboratories iCycler. In order to
address PON2 protein mass in cancer samples, pooled tumor, or normal tissue
western blots were purchased from Assay Depot; PON2 was normalized to both
GAPDH and p38-MAPK.
Figure 8 PON2 does not alter ligand-induced caspase activation. Naive or PON2-GFP overexpressing cells were treated with various concentrations of TRAIL and
analyzed for caspase-8 activity after 2h (a), or with 100ng/ml TRAIL and analyzed for caspase-3/7 activity after 6h (b), or 1 or 3ng/ml TRAIL followed by determination of
intracellular ATP levels after 16h (c). We used low TRAIL doses in C, as higher concentrationskilled cells too rapidly such that an overwhelming stimulus could have masked
potential effects of PON2. (d) Named cells were treated for 16h with TNF-a (10ng/ml) or actinomycin D (1mg/ml) or both; subsequently, caspase-3/7 activity was assessed.
Symbols represent mean±S.E.M. n¼3–6 independent experiments (>duplicates each); n.s.¼not signiﬁcant; ***Po0.001
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Cell Death and DiseaseSoftware, statistics and image acquisition. GraphPad Prism-5 was
used for calculations, non-linear regression curve ﬁtting or statistical evaluation
using1-/2-wayANOVAwith Bonferroni’s multiplecomparisons posttest(see Figure
legends). Po0.05 was considered signiﬁcant. Adobe Photoshop software was
used for image acquisition. If necessary, only brightness and/or contrast were
changed simultaneously for all areas of any blot.
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